Lymphoproliferative skin lesion as a previously unreported adverse event detected in a patient receiving mSTR TB treatment. Journal of Pharmacovigilance and Drug Research, [S. l.], v. 3, n. 2, p. 34–37, 2022. DOI: 10.53411/jpadr.2022.3.2.7. Disponível em: http://jpadr.com/index.php/jpadr/article/view/62. Acesso em: 12 nov. 2026.